Du är här


Swedish Orphan Biovitrum AB (publ): Invitation - Presentation of Sobi's fourth quarter and full year results 2015

On 26 February 2016, at 08:00 CET,Swedish Orphan Biovitrum AB (publ)(Sobi)
will publish its report for the fourth quarter and full year 2015.

Financial analysts and media are invited to participate in a telephone
conference, which will include a presentation of the results, on the same day
at 12:30 CET. The event will be hosted by Sobi's CEO and President, Geoffrey
McDonough, and the presentation will be held in English.

The presentation can be followed live, or afterwards onwww.sobi.com. Slides
used in the presentation will be made available on Sobi's website prior to
the telephone conference.

To participate in the telephone conference, please call:
SE: +46 8 566 426 90
UK: +44 203 008 98 01
US: +1 855 831 59 44

Live audience

(The recording will be made available via the audience URL within three hours
after the live broadcast using the same link.)


About Sobi(TM)

Sobi is an international specialty healthcare company dedicated to rare
diseases. Sobi's mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Haemophilia, Inflammation and Genetic diseases. Sobi also markets
a portfolio of specialty and rare disease products for partner companies
across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion
(USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on
NASDAQ OMX Stockholm. More information is available atwww.sobi.com.

For more information please contact

| Media relations Investor relations |
| Oskar Bosson, Head of Communications Jörgen Winroth, Vice President, Head of Investor Relations |
| T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135 |
| oskar.bosson@sobi.com jorgen.winroth@sobi.com |
006e_Q4 and FY invitation


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Globenewswire


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.